Ivabradina Mylan Pharma

Ivabradine, the active ingredient in Ivabradina Mylan Pharma, is a If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate adult patients.

GNH USA supplies Ivabradina Mylan Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Mylan Pharma acts on the cardiac If current to lower heart rate in conditions where rate control improves outcomes.

Chronic stable angina pectoris: reduces the frequency of angina attacks by decreasing myocardial oxygen demand. Heart failure with reduced ejection fraction (NYHA class II‑III): improves symptoms and may lower hospitalization risk. Patients unable to tolerate beta‑blockers: provides heart‑rate reduction without affecting contractility or intracardiac conduction.

Adverse reactions may be observed with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia (resting heart rate <50 bpm) - Headache - Dizziness or light‑headedness - Fatigue - Nausea

Serious or Rare Side Effects: - Symptomatic bradyarrhythmias requiring medical intervention - Atrial fibrillation or other supraventricular tachyarrhythmias - Severe hypotension - Persistent visual loss or retinal disturbances - Allergic skin reactions (rash, pruritus)

Before prescribing Ivabradina Mylan Pharma, clinicians should consider several safety measures.

Assess baseline heart rate: ensure resting rate ≥60 bpm before initiation. Monitor ECG: watch for bradycardia or new arrhythmias during therapy. Caution in hepatic impairment: dose adjustment may be required. Avoid in severe hypotension or sick‑sinus syndrome. Contraindicated in patients with acute decompensated heart failure. Store at below 25°C: keep in the original pack, protect from moisture.

Ivabradina Mylan Pharma can interact with several drug classes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine exposure. - Concomitant bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - CYP3A4 inhibitors combined with diltiazem/verapamil: may cause severe bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may reduce efficacy. - Diuretics causing electrolyte shifts: monitor for arrhythmia risk. - Antihypertensive agents: observe for additive blood‑pressure lowering effects.